Compare Abeona Therapeutics Inc (ABEO) vs Jabil Inc (JBL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Jabil Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Jabil Inc trades at $317.36 (market cap $33.65B). The key difference: Jabil Inc is far larger — about 90.1× Abeona Therapeutics Inc's market cap, and Jabil Inc pays a 0.1% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | JBL | |
|---|---|---|
Market Cap | $373.32M | $33.65B |
Sector | Health | Technology |
52-Week High | $7.23 | $385.50 |
52-Week Low | $4.17 | $192.49 |
Enterprise Value | $228.22M | $36.18B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
JBL trades at $338.22, down 0.9% today, with technical indicators showing a bearish trend near support at $333. The stock has demonstrated strong earnings momentum, beating estimates for three consecutive quarters, and benefits from AI infrastructure demand driving revenue growth. Analyst consensus is split evenly between Buy and Hold ratings with a $436.50 price target suggesting significant upside potential.
The outlook remains positive due to AI-driven growth and margin expansion, though high valuation multiples and competitive pressures present risks. Recent manufacturing expansion in India and hyperscaler customer wins support long-term growth, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
